Molecular Predictors of Gemcitabine Response in Pancreatic Cancer

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2011 Nov 24

PMID 22110842

Citations 39

Authors

Ioannis A Voutsadakis

Affiliations

Soon will be listed here.

Abstract

Gemcitabine is one of the most used anti-neoplastic drugs with documented activity in almost all major localizations of cancer. In pancreatic cancer treatment, gemcitabine occupies a prominent place as a first line chemotherapy, partly because of the paucity of other efficacious chemotherapy options. In fact, only a minority of pancreatic cancer patients display a response or even stability of disease with the drug. There are currently no clinically applicable means of predicting which patient will derive a clinical benefit from gemcitabine although several proposed markers have been studied. These markers are proteins involved in drug up-take, activation and catabolism or proteins that define the ability of the cell to undergo apoptosis in response to the drug. Several of these markers are reviewed in this paper. We also briefly discuss the possible role of stem cells in drug resistance to gemcitabine.

Citing Articles

Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.

Ogunleye A, Piyawajanusorn C, Ghislat G, Ballester P Health Data Sci. 2024; 4:0108.

PMID: 38486621 PMC: 10904073. DOI: 10.34133/hds.0108.

AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.

Ingle K, LaComb J, Graves L, Baines A, Bialkowska A PLoS One. 2023; 18(11):e0294065.

PMID: 37943821 PMC: 10635512. DOI: 10.1371/journal.pone.0294065.

Synthesis and anticancer evaluation of acetylated-lysine conjugated gemcitabine prodrugs.

Wang M, Qu K, Zhao P, Yin X, Meng Y, Herdewijn P RSC Med Chem. 2023; 14(8):1572-1580.

PMID: 37593582 PMC: 10429768. DOI: 10.1039/d3md00190c.

How Cryo-EM Has Expanded Our Understanding of Membrane Transporters.

Baril S, Gose T, Schuetz J Drug Metab Dispos. 2023; 51(8):904-922.

PMID: 37438132 PMC: 10353158. DOI: 10.1124/dmd.122.001004.

Design and Development of a New Type of Hybrid PLGA/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells.

Markowski A, Jaromin A, Migdal P, Olczak E, Zygmunt A, Zaremba-Czogalla M Int J Mol Sci. 2022; 23(10).

PMID: 35628352 PMC: 9143619. DOI: 10.3390/ijms23105536.

References

Marechal R, Mackey J, Lai R, Demetter P, Peeters M, Polus M . Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res. 2009; 15(8):2913-9. DOI: 10.1158/1078-0432.CCR-08-2080. View

Pham N, Tsao M, Cao P, Hedley D . Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pancreas. 2007; 35(3):e16-26. DOI: 10.1097/mpa.0b013e318095a747. View

Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R . Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity. Anticancer Res. 2010; 30(10):3919-25. View

Farrell J, Elsaleh H, Garcia M, Lai R, Ammar A, Regine W . Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2008; 136(1):187-95. DOI: 10.1053/j.gastro.2008.09.067. View

Vincent T, Neve E, Johnson J, Kukalev A, Rojo F, Albanell J . A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nat Cell Biol. 2009; 11(8):943-50. PMC: 3769970. DOI: 10.1038/ncb1905. View

Sebastiani V, Ricci F, Rubio-Viqueira B, Rubio-Viquiera B, Kulesza P, Yeo C . Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006; 12(8):2492-7. PMC: 3619210. DOI: 10.1158/1078-0432.CCR-05-2655. View

Kunnumakkara A, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S . {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 2010; 70(21):8695-705. PMC: 2970705. DOI: 10.1158/0008-5472.CAN-10-2318. View

Ng S, Tsao M, Nicklee T, Hedley D . Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res. 2001; 7(10):3269-75. View

Mamaghani S, Patel S, Hedley D . Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009; 9:132. PMC: 2685435. DOI: 10.1186/1471-2407-9-132. View

10.

Marechal R, Mackey J, Lai R, Demetter P, Peeters M, Polus M . Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma. Cancer. 2010; 116(22):5200-6. DOI: 10.1002/cncr.25303. View

11.

Nakahira S, Nakamori S, Tsujie M, Takeda S, Sugimoto K, Takahashi Y . Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 2008; 28(1A):179-86. View

12.

Park J, Lee E, Esau C, Schmittgen T . Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009; 38(7):e190-9. DOI: 10.1097/MPA.0b013e3181ba82e1. View

13.

Hagmann W, Jesnowski R, Matthias Lohr J . Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010; 12(9):740-7. PMC: 2933694. DOI: 10.1593/neo.10576. View

14.

Mackey J, Mani R, Selner M, Mowles D, Young J, Belt J . Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998; 58(19):4349-57. View

15.

Wong A, Soo R, Yong W, Innocenti F . Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009; 41(2):77-88. DOI: 10.1080/03602530902741828. View

16.

Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang Z, Chiao P . Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005; 65(19):9064-72. DOI: 10.1158/0008-5472.CAN-05-1330. View

17.

Olive K, Jacobetz M, Davidson C, Gopinathan A, McIntyre D, Honess D . Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933):1457-61. PMC: 2998180. DOI: 10.1126/science.1171362. View

18.

Rejiba S, Bigand C, Parmentier C, Hajri A . Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia. 2009; 11(7):637-50. PMC: 2697350. DOI: 10.1593/neo.81686. View

19.

Ueno H, Kiyosawa K, Kaniwa N . Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?. Br J Cancer. 2007; 97(2):145-51. PMC: 2360307. DOI: 10.1038/sj.bjc.6603860. View

20.

Kreutzer J, Ruzzene M, Guerra B . Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells. BMC Cancer. 2010; 10:440. PMC: 2931491. DOI: 10.1186/1471-2407-10-440. View